LENZ

LENZ Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $515.66 million. The company's financial health is marked by significant net losses and negative returns on equity and assets. LENZ reported a net income loss of $58.883 million and an EBITDA loss of $67.695 million for the trailing twelve months, while its gross margin stands at 100.0%. The operating margin and profit margin are -151.1% and 0.0%, respectively. On the balance sheet side, LENZ has a cash position of $202.17 million and debt of $954,000. LENZ's valuation metrics indicate a negative forward P/E ratio of -5.72 and an EV/EBITDA of -4.42, suggesting potential undervaluation from a certain perspective. The price to book ratio stands at 2.43, while the price to sales ratio is 29.47. Notably, LENZ does not pay dividends.